15 results on '"Mawhinney, L."'
Search Results
2. Inflammation and cancer: macrophage migration inhibitory factor (MIF)—the potential missing link
- Author
-
Conroy, H., Mawhinney, L., and Donnelly, S. C.
- Published
- 2010
- Full Text
- View/download PDF
3. Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis
- Author
-
Cooke, G, primary, Kamal, I, additional, Strengert, M, additional, Hams, E, additional, Mawhinney, L, additional, Tynan, A, additional, O’Reilly, C, additional, O’Dwyer, D N, additional, Kunkel, S L, additional, Knaus, U G, additional, Shields, D C, additional, Moller, D R, additional, Bowie, A G, additional, Fallon, P G, additional, Hogaboam, C M, additional, Armstrong, M E, additional, and Donnelly, S C, additional
- Published
- 2017
- Full Text
- View/download PDF
4. Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis.
- Author
-
Kunkel, S. L., Cooke, G., Strengert, M., O'Dwyer, D. N., Knaus, U. G., Kamal, I., Hams, E., Mawhinney, L., Tynan, A., O'Reilly, C., Armstrong, M. E., Donnelly, S. C., Fallon, P. G., Shields, D. C., Moller, D. R., Bowie, A. G., and Hogaboam, C. M.
- Subjects
SARCOIDOSIS ,TOLL-like receptors ,GENETIC polymorphisms ,PHENOTYPES ,ETIOLOGY of diseases ,GRANULOMA ,GENETICS - Abstract
Background/Introduction: Sarcoidosis is a multi-systemic disorder of unknown etiology, characterized by the presence of non-caseating granulomas in target organs. In 90% of cases, there is thoracic involvement. Fifty to seventy percent of pulmonary sarcoidosis patients will experience acute, self-limiting disease. For the subgroup of patients who develop persistent disease, no targeted therapy is currently available. Aim: To investigate the potential of the single nucleotide polymorphism (SNP), Toll-like receptor 3 Leu412Phe (TLR3 L412F; rs3775291), as a causative factor in the development of and in disease persistence in pulmonary sarcoidosis. To investigate the functionality of TLR3 L412F in vitro in primary human lung fibroblasts from pulmonary sarcoidosis patients. Design: SNP-genotyping and cellular assays, respectively, were used to investigate the role of TLR3 L412F in the development of persistent pulmonary sarcoidosis. Methods: Cohorts of Irish sarcoidosis patients (n=228), healthy Irish controls (n=263) and a secondary cohort of American sarcoidosis patients (n=123) were genotyped for TLR3 L412F. Additionally, the effect of TLR3 L412F in primary lung fibroblasts from pulmonary sarcoidosis patients was quantitated following TLR3 activation in the context of cytokine and type I interferon production, TLR3 expression and apoptotic- and fibroproliferative-responses. Results: We report a significant association between TLR3 L412F and persistent clinical disease in two cohorts of Irish and American Caucasians with pulmonary sarcoidosis. Furthermore, activation of TLR3 in primary lung fibroblasts from 412 Fhomozygous pulmonary sarcoidosis patients resulted in reduced IFN-β and TLR3 expression, reduced apoptosis- and dysregulated fibroproliferative-responses compared with TLR3 wild-type patients. Discussion/Conclusion: This study identifies defective TLR3 function as a previously unidentified factor in persistent clinical disease in pulmonary sarcoidosis and reveals TLR3 L412F as a candidate biomarker. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Hypophysectomy Results in a Loss of Connexin Gap Junction Protein from the Adrenal Cortex
- Author
-
Davis, K. T., primary, McDuffie, I., additional, Mawhinney, L. A., additional, and Murray, S. A., additional
- Published
- 2000
- Full Text
- View/download PDF
6. Responding to the times: Adapting an evaluation study during a dual pandemic.
- Author
-
Mawhinney L, Drame ER, Bowe AG, Duval-Diop D, Kares FR, and Santos P
- Subjects
- Humans, Pandemics, Program Evaluation, Police, COVID-19
- Abstract
This paper is a critical essay to discuss an original methodological design for an equity school evaluation in diverse-by-design schools. The evaluation was to gather a broad swathe of data necessary to provide detailed insights on diverse-by-design schools in diversity, equity, and inclusion (DEI) practices. We chronicle and critically explore the methodological pivots generated by the research team as we conducted this research against the backdrop of both the COVID-19 pandemic and US nationwide protests in response to the murder of George Floyd and countless other Black people at the hands of the police. We challenge our own use of equity in our research design by centering school communities through agency of partnership., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit Pseudomonas aeruginosa -induced inflammation and biofilm formation.
- Author
-
Doroudian M, O'Neill A, O'Reilly C, Tynan A, Mawhinney L, McElroy A, Webster SS, MacLoughlin R, Volkov Y, E Armstrong M, A O'Toole G, Prina-Mello A, and C Donnelly S
- Subjects
- Biofilms, Humans, Inflammation drug therapy, Pseudomonas aeruginosa, Macrophage Migration-Inhibitory Factors, Nanoparticles, Pharmaceutical Preparations, Pseudomonas Infections drug therapy
- Abstract
Aim: Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine, which has been shown to promote disease severity in cystic fibrosis. Methods : In this study, aerosolized drug-loaded nanoparticles containing SCD-19, an inhibitor of MIF's tautomerase enzymatic activity, were developed and characterized. Results: The aerosolized nanoparticles had an optimal droplet size distribution for deep lung deposition, with a high degree of biocompatibility and significant cellular uptake. Conclusion: For the first time, we have developed an aerosolized nano-formulation against MIF's enzymatic activity that achieved a significant reduction in the inflammatory response of macrophages, and inhibited Pseudomonas aeruginosa biofilm formation on airway epithelial cells. This represents a potential novel adjunctive therapy for the treatment of P. aeruginosa infection in cystic fibrosis.
- Published
- 2020
- Full Text
- View/download PDF
8. Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis.
- Author
-
Cooke G, Kamal I, Strengert M, Hams E, Mawhinney L, Tynan A, O'Reilly C, O'Dwyer DN, Kunkel SL, Knaus UG, Shields DC, Moller DR, Bowie AG, Fallon PG, Hogaboam CM, Armstrong ME, and Donnelly SC
- Subjects
- Adolescent, Adult, Aged, Case-Control Studies, Female, Genetic Predisposition to Disease, Humans, Ireland, Logistic Models, Male, Middle Aged, Phenotype, Young Adult, Polymorphism, Single Nucleotide, Sarcoidosis, Pulmonary genetics, Toll-Like Receptor 3 genetics
- Abstract
Background/introduction: Sarcoidosis is a multi-systemic disorder of unknown etiology, characterized by the presence of non-caseating granulomas in target organs. In 90% of cases, there is thoracic involvement. Fifty to seventy percent of pulmonary sarcoidosis patients will experience acute, self-limiting disease. For the subgroup of patients who develop persistent disease, no targeted therapy is currently available., Aim: To investigate the potential of the single nucleotide polymorphism (SNP), Toll-like receptor 3 Leu412Phe (TLR3 L412F; rs3775291), as a causative factor in the development of and in disease persistence in pulmonary sarcoidosis. To investigate the functionality of TLR3 L412F in vitro in primary human lung fibroblasts from pulmonary sarcoidosis patients., Design: SNP-genotyping and cellular assays, respectively, were used to investigate the role of TLR3 L412F in the development of persistent pulmonary sarcoidosis., Methods: Cohorts of Irish sarcoidosis patients (n = 228), healthy Irish controls (n = 263) and a secondary cohort of American sarcoidosis patients (n = 123) were genotyped for TLR3 L412F. Additionally, the effect of TLR3 L412F in primary lung fibroblasts from pulmonary sarcoidosis patients was quantitated following TLR3 activation in the context of cytokine and type I interferon production, TLR3 expression and apoptotic- and fibroproliferative-responses., Results: We report a significant association between TLR3 L412F and persistent clinical disease in two cohorts of Irish and American Caucasians with pulmonary sarcoidosis. Furthermore, activation of TLR3 in primary lung fibroblasts from 412 F-homozygous pulmonary sarcoidosis patients resulted in reduced IFN-β and TLR3 expression, reduced apoptosis- and dysregulated fibroproliferative-responses compared with TLR3 wild-type patients., Discussion/conclusion: This study identifies defective TLR3 function as a previously unidentified factor in persistent clinical disease in pulmonary sarcoidosis and reveals TLR3 L412F as a candidate biomarker.
- Published
- 2018
- Full Text
- View/download PDF
9. Macrophage migration inhibitory factor enhances Pseudomonas aeruginosa biofilm formation, potentially contributing to cystic fibrosis pathogenesis.
- Author
-
Tynan A, Mawhinney L, Armstrong ME, O'Reilly C, Kennedy S, Caraher E, Jülicher K, O'Dwyer D, Maher L, Schaffer K, Fabre A, McKone EF, Leng L, Bucala R, Bernhagen J, Cooke G, and Donnelly SC
- Subjects
- Animals, Biofilms growth & development, Cystic Fibrosis drug therapy, Cystic Fibrosis microbiology, Disease Models, Animal, Intramolecular Oxidoreductases pharmacology, Macrophage Migration-Inhibitory Factors pharmacology, Mice, Recombinant Proteins pharmacology, Tobramycin pharmacology, Cystic Fibrosis metabolism, Intramolecular Oxidoreductases metabolism, Macrophage Migration-Inhibitory Factors metabolism, Pseudomonas aeruginosa physiology
- Abstract
Macrophage migration inhibitory factor (MIF) is a key proinflammatory mediator that we have previously shown to be associated with an aggressive clinical phenotype in cystic fibrosis. It possesses unique tautomerase enzymatic activity. However, to date, no human-derived substrate has been identified that has the capacity to interact with this cytokine's unique tautomerase activity. This led us to hypothesize that MIF may have the capacity to interact with external substrates. We describe for the first time how Pseudomonas aeruginosa can utilize human recombinant MIF (rMIF) to significantly ( P < 0.01) enhance its endogenous biofilm formation. Our in vivo studies demonstrate that utilizing a small-molecular-weight inhibitor targeting MIF's tautomerase activity (SCD-19) significantly reduces the inflammatory response in a murine pulmonary chronic P. aeruginosa model. In addition, we show that in in vitro experiments, pretreatment of P. aeruginosa with rMIF is associated with reduced bacterial killing by tobramycin. Our novel findings support the concept of an anti-MIF strategy that targets this enzymatic activity as a potential future antibacterial therapeutic approach.-Tynan, A., Mawhinney, L., Armstrong, M. E., O'Reilly, C., Kennedy, S., Caraher, E., Jülicher, K., O'Dwyer, D., Maher, L., Schaffer, K., Fabre, A., McKone, E. F., Leng, L., Bucala, R., Bernhagen, J., Cooke, G., Donnelly, S. C. Macrophage migration inhibitory factor enhances Pseudomonas aeruginosa biofilm formation, potentially contributing to cystic fibrosis pathogenesis., (© FASEB.)
- Published
- 2017
- Full Text
- View/download PDF
10. Healthcare providers' perspectives on the acceptability and uptake of HPV vaccines in Zimbabwe.
- Author
-
Crann SE, Barata PC, Mitchell R, Mawhinney L, Thistle P, Chirenje ZM, and Stewart DE
- Subjects
- Adult, Female, Hospitals, Rural, Humans, Male, Zimbabwe ethnology, Attitude of Health Personnel ethnology, Health Knowledge, Attitudes, Practice ethnology, Papillomavirus Vaccines, Uterine Cervical Neoplasms prevention & control
- Abstract
Background: Human papillomavirus (HPV) vaccines are a critical strategy in the prevention of cervical cancer, especially in countries like Zimbabwe where cervical cancer screening rates are low. In Zimbabwe, cervical cancer is the leading cause of cancer-related deaths in women but the HPV vaccine is not yet widely available. This study examined healthcare providers': (1) perceptions of current hospital practices and issues in cervical cancer prevention and treatment in Zimbabwe; (2) knowledge of HPV and HPV vaccines; and (3) perspectives on introducing HPV vaccination programs in Zimbabwe, including potential facilitators and barriers to successful implementation., Method: In-depth semi-structured interviews were conducted at a rural hospital with 15 healthcare providers in Zimbabwe. Interviews included eight main questions and a number of additional probes that reflected the study's purpose. Data were analyzed using thematic analysis., Results: Participants reported that women are not consistently being screened for cervical cancer. There were generally low levels of knowledge about HPV and HPV vaccines, but participants asked many questions indicating a desire to learn more. Although they were highly supportive of implementing HPV vaccination programs in Zimbabwe, they also identified a number of likely psychosocial, cultural, and logistical barriers to successful implementation, including cost, vaccine schedule, and hospital infrastructure. However, participants also provided a number of culturally relevant solutions, including education and community engagement., Conclusion: This study provides insight from healthcare providers about barriers to implementation and possible solutions that can be used by policy makers, practitioners, and other stakeholders to facilitate the successful implementation of forthcoming HPV immunization programs in Zimbabwe.
- Published
- 2016
- Full Text
- View/download PDF
11. Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities.
- Author
-
O'Reilly C, Doroudian M, Mawhinney L, and Donnelly SC
- Subjects
- Humans, Intramolecular Oxidoreductases chemistry, Macrophage Migration-Inhibitory Factors chemistry, Neoplasms metabolism, Intramolecular Oxidoreductases drug effects, Macrophage Migration-Inhibitory Factors drug effects, Neoplasms therapy
- Abstract
Strong evidence has been presented linking chronic inflammation to the onset and pathogenesis of cancer. The multifunctional pro-inflammatory protein macrophage migration inhibitory factor (MIF) occupies a central role in the inflammatory pathway and has been implicated in the tumorigenesis, angiogenesis, and metastasis of many cancer phenotypes. This review highlights the current state of the art, which presents MIF, and the second member of the MIF structural superfamily, D-DT (MIF2), as significant mediators in the inflammatory-cancer axis. Although the mechanism by which MIF asserts its biological activity has yet to be fully understood, it has become clear in recent years that for certain phenotypes of cancer, MIF represents a valid therapeutic target. Current research efforts have focused on small molecule approaches that target MIF's unique tautomerase active site and neutralization of MIF with anti-MIF antibodies. These approaches have yielded promising results in a number of preclinical murine cancer models and have helped to increase our understanding of MIF biological activity. More recently, MIF's involvement in a number of key protein-protein interactions, such as with CD74 and HSP90, has been highlighted and provides a novel platform for the development of anti-MIF chemotherapeutic strategies in the future., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
12. Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer.
- Author
-
Mawhinney L, Armstrong ME, O' Reilly C, Bucala R, Leng L, Fingerle-Rowson G, Fayne D, Keane MP, Tynan A, Maher L, Cooke G, Lloyd D, Conroy H, and Donnelly SC
- Subjects
- Animals, Antineoplastic Agents pharmacology, Carcinoma, Lewis Lung metabolism, Carcinoma, Lewis Lung pathology, Cell Line, Dinoprostone metabolism, Female, Intramolecular Oxidoreductases genetics, Intramolecular Oxidoreductases metabolism, Isocoumarins pharmacology, Lipopolysaccharides, Lung drug effects, Lung pathology, Lung Neoplasms metabolism, Lung Neoplasms pathology, Macrophage Migration-Inhibitory Factors genetics, Macrophage Migration-Inhibitory Factors metabolism, Mice, Inbred C57BL, Mice, Knockout, Tumor Burden drug effects, Tumor Necrosis Factor-alpha metabolism, Antineoplastic Agents therapeutic use, Carcinoma, Lewis Lung drug therapy, Intramolecular Oxidoreductases antagonists & inhibitors, Isocoumarins therapeutic use, Lung Neoplasms drug therapy, Macrophage Migration-Inhibitory Factors antagonists & inhibitors
- Abstract
The cytokine macrophage migration inhibitory factor (MIF) possesses unique tautomerase enzymatic activity, which contributes to the biological functional activity of MIF. In this study, we investigated the effects of blocking the hydrophobic active site of the tautomerase activity of MIF in the pathogenesis of lung cancer. To address this, we initially established a Lewis lung carcinoma (LLC) murine model in Mif-KO and wild-type (WT) mice and compared tumor growth in a knock-in mouse model expressing a mutant MIF lacking enzymatic activity (Mif (P1G)). Primary tumor growth was significantly attenuated in both Mif-KO and Mif (P1G) mice compared with WT mice. We subsequently undertook a structure-based, virtual screen to identify putative small molecular weight inhibitors specific for the tautomerase enzymatic active site of MIF. From primary and secondary screens, the inhibitor SCD-19 was identified, which significantly attenuated the tautomerase enzymatic activity of MIF in vitro and in biological functional screens. In the LLC murine model, SCD-19, given intraperitoneally at the time of tumor inoculation, was found to significantly reduce primary tumor volume by 90% (p < 0.001) compared with the control treatment. To better replicate the human disease scenario, SCD-19 was given when the tumor was palpable (at d 7 after tumor inoculation) and, again, treatment was found to significantly reduce tumor volume by 81% (p < 0.001) compared with the control treatment. In this report, we identify a novel inhibitor that blocks the hydrophobic pocket of MIF, which houses its specific tautomerase enzymatic activity, and demonstrate that targeting this unique active site significantly attenuates lung cancer growth in in vitro and in vivo systems.
- Published
- 2015
- Full Text
- View/download PDF
13. Temporal changes in monocyte and macrophage subsets and microglial macrophages following spinal cord injury in the Lys-Egfp-ki mouse model.
- Author
-
Thawer SG, Mawhinney L, Chadwick K, de Chickera SN, Weaver LC, Brown A, and Dekaban GA
- Subjects
- Animals, Female, Flow Cytometry methods, Green Fluorescent Proteins, Macrophages classification, Male, Mice, Mice, Transgenic, Microglia classification, Microglia pathology, Monocytes classification, Muramidase, Spinal Cord Injuries blood, Time Factors, Disease Models, Animal, Macrophages immunology, Macrophages pathology, Microglia immunology, Monocytes immunology, Monocytes pathology, Spinal Cord Injuries immunology, Spinal Cord Injuries pathology
- Abstract
The role of hematogenous (hMΦ) and microglial (mMΦ) macrophages following spinal cord injury (SCI) remains unclear as they are not distinguished easily from each other in the lesion area. We have recently described the temporal and spatial response to SCI of each MΦ population using the lys-EGFP-ki mouse that enables EGFP(+) hMΦ to be distinguished from EGFP(-) mMΦ at the lesion site. In the present study, we characterized the response of monocyte and hMΦ subsets and mMΦ to SCI. We describe, for the first time, the responses of circulating classical (pro-inflammatory) and non-classical monocyte subsets to SCI. Additionally, we show the presence of classical and non-classical hMΦ at the SCI lesion. Importantly, we demonstrate that the 'classical pro-inflammatory' hMΦ respond in the acute (1d, 3d) stages of SCI while the 'non-classical' hMΦ respond in the sub-acute (7d, 14d) phase of SCI. At later time points (6weeks post injury) classical hMΦ return to the injury site. Our study offers new insight into the cellular inflammatory response that occurs after SCI and suggests that the timing and targets of anti-inflammatory therapies may be crucial to maximize neuroprotection at the acute and more chronic stages of SCI., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
14. Inflammation and cancer: macrophage migration inhibitory factor (MIF)--the potential missing link.
- Author
-
Conroy H, Mawhinney L, and Donnelly SC
- Subjects
- Animals, Biomarkers metabolism, Cell Hypoxia physiology, Disease Progression, Humans, Inflammation metabolism, Mice, Neoplasms blood supply, Neoplasms metabolism, Neovascularization, Pathologic etiology, Inflammation complications, Macrophage Migration-Inhibitory Factors physiology, Neoplasms etiology
- Abstract
Macrophage migration inhibitory factor (MIF) was the original cytokine, described almost 50 years ago and has since been revealed to be an important player in pro-inflammatory diseases. Recent work using MIF mouse models has revealed new roles for MIF. In this review, we present an increasing body of evidence implicating the key pro-inflammatory cytokine MIF in specific biological activities related directly to cancer growth or contributing towards a microenvironment favouring cancer progression.
- Published
- 2010
- Full Text
- View/download PDF
15. A monoclonal antibody to CD11d reduces the inflammatory infiltrate into the injured spinal cord: a potential neuroprotective treatment.
- Author
-
Saville LR, Pospisil CH, Mawhinney LA, Bao F, Simedrea FC, Peters AA, O'Connell PJ, Weaver LC, and Dekaban GA
- Subjects
- Animals, Antibodies, Monoclonal biosynthesis, Antibodies, Monoclonal metabolism, CD11 Antigens metabolism, Cell Movement immunology, Cross Reactions, Female, Humans, Integrin alpha Chains metabolism, Leukocytes immunology, Leukocytes metabolism, Myelitis immunology, Myelitis metabolism, Rats, Rats, Wistar, Spinal Cord Injuries immunology, Spinal Cord Injuries metabolism, Antibodies, Monoclonal therapeutic use, CD11 Antigens immunology, Integrin alpha Chains immunology, Myelitis prevention & control, Neuroprotective Agents pharmacology, Spinal Cord Injuries therapy
- Abstract
The accumulation of inflammatory cells in the lesion of a spinal cord injury (SCI) enhances secondary damage, resulting in further neurological impairment. High-dose methylprednisolone (MP) treatment is the only accepted treatment for inflammation secondary to human SCI but is minimally effective. Using a rat SCI model, we devised an anti-inflammatory treatment to block the infiltration of neutrophils and hematogenous monocyte/macrophages over the first 2 days postinjury by targeting the CD11dCD18 integrin. Anti-CD11d mAb administration following SCI effectively reduced neutrophil and macrophage infiltrate into lesions by 70% and 36%, respectively, over the first 72 h post-SCI. MP also reduced neutrophil and macrophage infiltrate by 60% and 28%, respectively, but by different mechanisms. The immunosuppression caused by anti-CD11d treatment was not sustained, as inflammatory cell numbers were not different from those observed in untreated SCI control animals at 7 days postinjury. In contrast, in MP-treated animals, the number of macrophages was still suppressed in the lesion while neutrophil numbers were significantly increased. These results suggest that anti-CD11d mAb treatment following SCI will minimize the destructive actions associated with early, uncontrolled leukocyte infiltration into the lesion while permitting the positive wound healing effects of macrophages at later time points.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.